SGLT2 Inhibitors in Type 2 Diabetes After Acute Heart Attack
Observes SGLT2 inhibitor drug use in adults with type 2 diabetes and recent heart attack.
Plain-language title generated from the registry record
Registry title: SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Seoul St. Mary's HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kiyuk Chang
- Trial code
- NCT05770687
- Record updated
- 3 January 2025
- Original description
Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction.Read full original descriptionShow less
Real World Observation of SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction.
The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.
Inclusion: Acute myocardial infarction who were treated with percutaneous coronary intervention; Type 2 diabetes mellitus; Started SGLT2 inhibitors <1 month before/after PCI.
Exclusion: Previous users of SGLT2 inhibitors; Type 1 diabetes mellitus; Insulin / GLP-1 analogue users; Pregnancy.